These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 9734559)

  • 1. Treatment of aggression in schizophrenia.
    Silver H; Kushnir M
    Am J Psychiatry; 1998 Sep; 155(9):1298. PubMed ID: 9734559
    [No Abstract]   [Full Text] [Related]  

  • 2. Carbamazepine and/or fluvoxamine drug interaction with risperidone in a patient on multiple psychotropic medications.
    Alfaro CL; Nicolson R; Lenane M; Rapoport JL
    Ann Pharmacother; 2000 Jan; 34(1):122-3. PubMed ID: 10669197
    [No Abstract]   [Full Text] [Related]  

  • 3. Aggression and schizophrenia: efficacy of risperidone.
    Buckley PF; Ibrahim ZY; Singer B; Orr B; Donenwirth K; Brar PS
    J Am Acad Psychiatry Law; 1997; 25(2):173-81. PubMed ID: 9213289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risperidone for exclusively negative symptoms.
    Lane HY; Liu CC; Chang WH
    Am J Psychiatry; 1999 Feb; 156(2):335. PubMed ID: 9989576
    [No Abstract]   [Full Text] [Related]  

  • 5. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.
    Citrome L; Shope CB; Nolan KA; Czobor P; Volavka J
    Int Clin Psychopharmacol; 2007 Nov; 22(6):356-62. PubMed ID: 17917554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.
    Raskin S; Katz G; Zislin Z; Knobler HY; Durst R
    Acta Psychiatr Scand; 2000 Apr; 101(4):334-6. PubMed ID: 10782556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-adrenergic blockers for aggressive behavior in schizophrenia.
    Am J Psychiatry; 1987 Apr; 144(4):538-9. PubMed ID: 2882699
    [No Abstract]   [Full Text] [Related]  

  • 9. [Aggressiveness and residual schizophrenia].
    Manzano JM; Pereira Y; Valderrama ML; Llorca G; Ledesma A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1992; 20(4):183-8. PubMed ID: 1529749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical response of aggressive schizophrenics to oral tryptophan.
    Morand C; Young SN; Ervin FR
    Biol Psychiatry; 1983 May; 18(5):575-8. PubMed ID: 6860730
    [No Abstract]   [Full Text] [Related]  

  • 11. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 14. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
    Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
    J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curious cases--The curious case of a man with schizophrenia and excessive aggression.
    van Dijk DA; Enterman JH
    Schizophr Bull; 2012 Nov; 38(6):1128-9. PubMed ID: 22472475
    [No Abstract]   [Full Text] [Related]  

  • 17. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic treatment of schizophrenics at risk for violence.
    Soyka M
    Pharmacopsychiatry; 2001 Jan; 34(1):43-4. PubMed ID: 11229622
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial.
    Teranishi M; Kurita M; Nishino S; Takeyoshi K; Numata Y; Sato T; Tateno A; Okubo Y
    J Clin Psychopharmacol; 2013 Oct; 33(5):600-7. PubMed ID: 23948783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.